COVID-19 Update

A message from our CEO

 

Dear valued partner,

As coronavirus (COVID-19) continues to spread, we are committed to do everything we can to ensure the health and safety of our customers and our employees worldwide, while maintaining global supply security. We are closely monitoring the progress of the COVID-19 pandemic, in order to take all necessary precautions to keep our employees safe and our GMP manufacturing facility clear of any risks related to COVID-19. This includes adhering to recommendations from the WHO and the local health authorities.

We are protecting the health and safety of our employees and partners
We have implemented several precautions to protect the well-being of our employees. Our workforce that is able to work from home has been strongly encouraged to do so. We apply the recommended hygiene rules and do not allow any person from a risk/restricted area to enter our facility. We have also implemented business travel and in-person meeting restrictions for the coming weeks, thus protecting our traveling employees as well as our customers and partners.

We continue to deliver our products

We would like to reassure you that we are very closely monitoring the situation with the goal of maintaining global supplies of our products. CellGenix has an in-house stock of raw materials and consumables. In addition, we have stockpiled finished products as well as product intermediates in sufficient amounts. We don’t anticipate that the COVID-19 outbreak will impact the near-term global supply of our products.

In case you have any questions or concerns, please contact our customer service. Our customer service can be reached during our regular business hours and will maintain to process your requests as fast as possible.

CellGenix will continue to monitor the situation very closely and will communicate updates should they become necessary. We’re committed to working through these challenging circumstances with you together.

We wish all of you and your families to stay healthy.

Sincerely,

Felicia M. Rosenthal

CEO CellGenix